The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies

Journal of Neurochemistry

Volumn 110, Issue 6, 2009, Pages 1737-1765

  Bauer, Peter O ^a   Nukina, Nobuyuki ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

CAG repeat; Huntingtin; Huntington's disease; Pathogenesis; Polyglutamine; Therapy

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; AMILORIDE; ANTIOXIDANT; BENZAMIL; BUTYRIC ACID; CLIOQUINOL; CONGO RED; CREATINE; CYSTAMINE; DICHLOROACETIC ACID; HEAT SHOCK PROTEIN; HYDROXAMIC ACID; LITHIUM; MINOCYCLINE; MUTANT PROTEIN; POLYGLUTAMINE; PROTEASOME; REMACEMIDE; RESVERATROL; RILUZOLE; ROLIPRAM; SUMO PROTEIN; TANESPIMYCIN; TAUROURSODEOXYCHOLIC ACID; TEPRENONE; THIOCTIC ACID; TREHALOSE; UBIDECARENONE; UNINDEXED DRUG;

APOPTOSIS; DEATH; DENTATORUBROPALLIDOLUYSIAN ATROPHY; ENERGY METABOLISM; EXCITOTOXICITY; GENE LOCUS; GENE SILENCING; HUNTINGTON CHOREA; MENTAL DETERIORATION; MITOCHONDRION; NERVE CELL; NERVE CELL NECROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SPINAL MUSCULAR ATROPHY; SPINOCEREBELLAR DEGENERATION; TRANSCRIPTION REGULATION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MUTATION; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; PEPTIDES; PROTEIN FOLDING; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 69949170793     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06302.x     Document Type: Review

References (359)

1. Alonso I., Barros J., Tuna A., Coelho J., Sequeiros J., Silveira I. Coutinho P. (2003) Phenotypes of spinocerebellar ataxia type 6 and familial hemiplegic migraine caused by a unique CACNA1A missense mutation in patients from a large family. Arch. Neurol. 60, 610 614.
2. Al-Ramahi I., Lam Y. C., Chen H. K. et al. (2006) CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J. Biol. Chem. 281, 26714 26724.
3. Andreassen O. A., Dedeoglu A., Ferrante R. J. et al. (2001a) Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8, 479 491.
4. Andreassen O. A., Ferrante R. J., Huang H. M. et al. (2001b) Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann. Neurol. 50, 112 117.
5. Apostolinas S., Rajendren G., Dobrjansky A. Gibson M. J. (1999) Androgen receptor immunoreactivity in specific neural regions in normal and hypogonadal male mice: effect of androgens. Brain Res. 817, 19 24.
6. Aronin N., Kim M., Laforet G. DiFiglia M. (1999) Are there multiple pathways in the pathogenesis of Huntington's disease? Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 995 1003.
7. Arrasate M., Mitra S., Schweitzer E. S., Segal M. R. Finkbeiner S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805 810.
8. Atwal R. S., Xia J., Pinchev D., Taylor J., Epand R. M. Truant R. (2007) Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Genet. 16, 2600 2615.
9. Bae B. I., Xu H., Igarashi S. et al. (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47, 29 41.
10. Ballinger C. A., Connell P., Wu Y., Hu Z., Thompson L. J., Yin L. Y. Patterson C. (1999) Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol. 19, 4535 4545.
11. Banno H., Katsuno M., Suzuki K. et al. (2009) Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann. Neurol. 65, 140 150.
12. Bates G. P. Gonitel R. (2006) Mouse models of triplet repeat diseases. Mol. Biotechnol. 32, 147 158.
13. Bates G. P. Hockly E. (2003) Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? Curr. Opin. Neurol. 16, 465 470.
14. Bauer P., Kraus J., Matoska V., Brouckova M., Zumrova A. Goetz P. (2004a) Large de novo expansion of CAG repeats in patient with sporadic spinocerebellar ataxia type 7. J. Neurol. 251, 1023 1024.
15. Bauer P. O., Zumrova A., Matoska V., Mitsui K. Goetz P. (2004b) Can ataxin-2 be down-regulated by allele-specific de novo DNA methylation in SCA2 patients? Med. Hypotheses 63, 1018 1023.
16. Bauer P. O., Matoska V., Zumrova A., Boday A., Doi H., Marikova T. Goetz P. (2005a) Genotype/phenotype correlation in a SCA1 family: anticipation without CAG expansion. J. Appl. Genet. 46, 325 328.
17. Bauer P. O., Zumrova A., Matoska V., Marikova T., Krilova S., Boday A., Singh B. Goetz P. (2005b) Absence of spinocerebellar ataxia type 3/Machado-Joseph disease within ataxic patients in the Czech population. Eur. J. Neurol. 12, 851 857.
18. Bauer P. O., Wong H. K., Oyama F., Goswami A., Okuno M., Kino Y., Miyazaki H. Nukina N. (2009) Inhibition of rho kinases enhances the degradation of mutant huntingtin. J. Biol. Chem. 284, 13153 13164.
19. Beal M. F. Ferrante R. J. (2004) Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5, 373 384.
20. Beal M. F., Brouillet E., Jenkins B., Henshaw R., Rosen B. Hyman B. T. (1993) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61, 1147 1150.
21. Becher M. W., Kotzuk J. A., Sharp A. H., Davies S. W., Bates G. P., Price D. L. Ross C. A. (1998) Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol. Dis. 4, 387 397.
22. Beister A., Kraus P., Kuhn W., Dose M., Weindl A. Gerlach M. (2004) The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J. Neural Transm. Suppl. 68, 117 122.
23. Bence N. F., Sampat R. M. Kopito R. R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552 1555.
24. Benn C. L., Sun T., Sadri-Vakili G., McFarland K. N., DiRocco D. P., Yohrling G. J., Clark T. W., Bouzou B. Cha J. H. (2008) Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J. Neurosci. 28, 10720 10733.
25. Bennett E. J., Shaler T. A., Woodman B., Ryu K. Y., Zaitseva T. S., Becker C. H., Bates G. P., Schulman H. Kopito R. R. (2007) Global changes to the ubiquitin system in Huntington's disease. Nature 448, 704 708.
26. Bercovich B., Stancovski I., Mayer A., Blumenfeld N., Laszlo A., Schwartz A. L. Ciechanover A. (1997) Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70. J. Biol. Chem. 272, 9002 9010.
27. Berke S. J., Schmied F. A., Brunt E. R., Ellerby L. M. Paulson H. L. (2004) Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J. Neurochem. 89, 908 918.
28. Bezprozvanny I. (2007) Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease. Subcell. Biochem. 45, 323 335.
29. Bezprozvanny I. Hayden M. R. (2004) Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 322, 1310 1317.
30. Bhattacharyya A., Thakur A. K., Chellgren V. M., Thiagarajan G., Williams A. D., Chellgren B. W., Creamer T. P. Wetzel R. (2006) Oligoproline effects on polyglutamine conformation and aggregation. J. Mol. Biol. 355, 524 535.
31. Bingol B. Schuman E. M. (2006) Activity-dependent dynamics and sequestration of proteasomes in dendritic spines. Nature 441, 1144 1148.
32. Blier P. de Montigny C. (1994) Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15, 220 226.
33. Bonelli R. M., Hodl A. K., Hofmann P. Kapfhammer H. P. (2004) Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int. Clin. Psychopharmacol. 19, 337 342.
34. Bonini N. M. La Spada A. R. (2005) Silencing polyglutamine degeneration with RNAi. Neuron 48, 715 718.
35. Brooks B. P. Fischbeck K. H. (1995) Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. Trends Neurosci. 18, 459 461.
36. Brouillet E., Hantraye P., Ferrante R. J., Dolan R., Leroy-Willig A., Kowall N. W. Beal M. F. (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl Acad. Sci. USA 92, 7105 7109.
37. Browne S. E. Beal M. F. (2006) Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal. 8, 2061 2073.
38. Cauchi R. J. van den Heuvel M. (2006) The fly as a model for neurodegenerative diseases: is it worth the jump? Neurodegener. Dis. 3, 338 356.
39. Cepeda C., Hurst R. S., Calvert C. R., Hernandez-Echeagaray E., Nguyen O. K., Jocoy E., Christian L. J., Ariano M. A. Levine M. S. (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 23, 961 969.
40. Chai Y., Koppenhafer S. L., Bonini N. M. Paulson H. L. (1999a) Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci. 19, 10338 10347.
41. Chai Y., Koppenhafer S. L., Shoesmith S. J., Perez M. K. Paulson H. L. (1999b) Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum. Mol. Genet. 8, 673 682.
42. Chan E. Y., Luthi-Carter R., Strand A. et al. (2002) Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum. Mol. Genet. 11, 1939 1951.
43. Chang D. T., Rintoul G. L., Pandipati S. Reynolds I. J. (2006) Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol. Dis. 22, 388 400.
44. Chen M., Ona V. O., Li M. et al. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6, 797 801.
45. Chen H. K., Fernandez-Funez P., Acevedo S. F. et al. (2003) Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113, 457 468.
46. Chen W. L., Lin J. W., Huang H. J., Wang S. M., Su M. T., Lee-Chen G. J., Chen C. M. Hsieh-Li H. M. (2008a) SCA8 mRNA expression suggests an antisense regulation of KLHL1 and correlates to SCA8 pathology. Brain Res. 1233, 176 184.
47. Chen X., Tang T. S., Tu H., Nelson O., Pook M., Hammer R., Nukina N. Bezprozvanny I. (2008b) Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J. Neurosci. 28, 12713 12724.
48. de Chiara C., Menon R. P., Dal Piaz F., Calder L. Pastore A. (2005) Polyglutamine is not all: the functional role of the AXH domain in the ataxin-1 protein. J. Mol. Biol. 354, 883 893.
49. Choo Y. S., Johnson G. V., MacDonald M., Detloff P. J. Lesort M. (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13, 1407 1420.
50. Chou A. H., Yeh T. H., Kuo Y. L., Kao Y. C., Jou M. J., Hsu C. Y., Tsai S. R., Kakizuka A. Wang H. L. (2006) Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL. Neurobiol. Dis. 21, 333 345.
51. Ciechanover A. (2006) Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Exp. Biol. Med. (Maywood) 231, 1197 1211. (Pubitemid 44050466)
52. Colin E., Zala D., Liot G., Rangone H., Borrell-Pages M., Li X. J., Saudou F. Humbert S. (2008) Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J. 27, 2124 2134.
53. Colomer Gould V. F., Goti D., Pearce D. et al. (2007) A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Neurobiol. Dis. 27, 362 369.
54. Cooper J. K., Schilling G., Peters M. F. et al. (1998) Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet. 7, 783 790.
55. Cornett J., Cao F., Wang C. E., Ross C. A., Bates G. P., Li S. H. Li X. J. (2005) Polyglutamine expansion of huntingtin impairs its nuclear export. Nat. Genet. 37, 198 204.
56. Cui L., Jeong H., Borovecki F., Parkhurst C. N., Tanese N. Krainc D. (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 59 69.
57. Cummings C. J., Mancini M. A., Antalffy B., DeFranco D. B., Orr H. T. Zoghbi H. Y. (1998) Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 19, 148 154.
58. Cummings C. J., Reinstein E., Sun Y., Antalffy B., Jiang Y., Ciechanover A., Orr H. T., Beaudet A. L. Zoghbi H. Y. (1999) Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24, 879 892.
59. Cummings C. J., Sun Y., Opal P., Antalffy B., Mestril R., Orr H. T., Dillmann W. H. Zoghbi H. Y. (2001) Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum. Mol. Genet. 10, 1511 1518.
60. Davies S. W., Turmaine M., Cozens B. A. et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537 548.
61. Davies J. E., Sarkar S. Rubinsztein D. C. (2007) The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias. BMC Biochem. 8 (Suppl. 1 S2.
62. Dedeoglu A., Kubilus J. K., Jeitner T. M. et al. (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22, 8942 8950.
63. van Dellen A., Blakemore C., Deacon R., York D. Hannan A. J. (2000) Delaying the onset of Huntington's in mice. Nature 404, 721 722.
64. DeMarch Z., Giampa C., Patassini S., Bernardi G. Fusco F. R. (2008) Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 30, 375 387.
65. DiFiglia M. (2002) Huntingtin fragments that aggregate go their separate ways. Mol. Cell 10, 224 225.
66. DiFiglia M., Sapp E., Chase K. O., Davies S. W., Bates G. P., Vonsattel J. P. Aronin N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990 1993.
67. Doi H., Mitsui K., Kurosawa M., Machida Y., Kuroiwa Y. Nukina N. (2004) Identification of ubiquitin-interacting proteins in purified polyglutamine aggregates. FEBS Lett. 571, 171 176.
68. Doi H., Okamura K., Bauer P. O. et al. (2008) RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells. J. Biol. Chem. 283, 6489 6500.
69. Driscoll M. Gerstbrein B. (2003) Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nat. Rev. Genet. 4, 181 194.
70. Duan W., Guo Z., Jiang H., Ladenheim B., Xu X., Cadet J. L. Mattson M. P. (2004) Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann. Neurol. 55, 590 594.
71. Duan W., Peng Q., Masuda N. et al. (2008) Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol. Dis. 30, 312 322.
72. Dunah A. W., Jeong H., Griffin A. et al. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238 2243.
73. Dyer R. B. McMurray C. T. (2001) Mutant protein in Huntington disease is resistant to proteolysis in affected brain. Nat. Genet. 29, 270 278.
74. Ellerby L. M., Andrusiak R. L., Wellington C. L. et al. (1999) Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J. Biol. Chem. 274, 8730 8736.
75. Ellisdon A. M., Thomas B. Bottomley S. P. (2006) The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J. Biol. Chem. 281, 16888 16896.
76. Elsasser S., Chandler-Militello D., Muller B., Hanna J. Finley D. (2004) Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome. J. Biol. Chem. 279, 26817 26822.
77. Emamian E. S., Kaytor M. D., Duvick L. A., Zu T., Tousey S. K., Zoghbi H. Y., Clark H. B. Orr H. T. (2003) Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38, 375 387.
78. Fei E., Jia N., Zhang T. et al. (2007) Phosphorylation of ataxin-3 by glycogen synthase kinase 3beta at serine 256 regulates the aggregation of ataxin-3. Biochem. Biophys. Res. Commun. 357, 487 492.
79. Fernandes H. B., Baimbridge K. G., Church J., Hayden M. R. Raymond L. A. (2007) Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J. Neurosci. 27, 13614 13623.
80. Fernandez-Funez P., Nino-Rosales M. L., de Gouyon B. et al. (2000) Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408, 101 106.
81. Ferrante R. J. (2009) Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim. Biophys. Acta 1792, 506 520.
82. Ferrante R. J., Andreassen O. A., Jenkins B. G., Dedeoglu A., Kuemmerle S., Kubilus J. K., Kaddurah-Daouk R., Hersch S. M. Beal M. F. (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20, 4389 4397.
83. Ferrante R. J., Andreassen O. A., Dedeoglu A., Ferrante K. L., Jenkins B. G., Hersch S. M. Beal M. F. (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22, 1592 1599.
84. Ferrante R. J., Kubilus J. K., Lee J. et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418 9427.
85. Ferrante R. J., Ryu H., Kubilus J. K. et al. (2004) Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J. Neurosci. 24, 10335 10342.
86. Friedman M. J., Shah A. G., Fang Z. H., Ward E. G., Warren S. T., Li S. Li X. J. (2007) Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat. Neurosci. 10, 1519 1528.
87. Friedman M. J., Wang C. E., Li X. J. Li S. (2008) Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity. J. Biol. Chem. 283, 8283 8290.
88. Fujikake N., Nagai Y., Popiel H. A., Okamoto Y., Yamaguchi M. Toda T. (2008) Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J. Biol. Chem. 283, 26188 26197.
89. Furukawa Y., Kaneko K., Matsumoto G., Kurosawa M. Nukina N. (2009) Cross-seeding fibrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine diseases. J. Neurosci. 29, 5153 5162.
90. Gafni J. Ellerby L. M. (2002) Calpain activation in Huntington's disease. J. Neurosci. 22, 4842 4849.
91. Gafni J., Hermel E., Young J. E., Wellington C. L., Hayden M. R. Ellerby L. M. (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 279, 20211 20220.
92. Gardian G., Browne S. E., Choi D. K. et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 280, 556 563.
93. Gatchel J. R. Zoghbi H. Y. (2005) Diseases of unstable repeat expansion: mechanisms and common principles. Nat. Rev. Genet. 6, 743 755.
94. Gervais F. G., Singaraja R., Xanthoudakis S. et al. (2002) Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat. Cell Biol. 4, 95 105.
95. Giampa C., Middei S., Patassini S., Borreca A., Marullo F., Laurenti D., Bernardi G., Ammassari-Teule M. Fusco F. R. (2009) Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Eur. J. Neurosci. 29, 902 910.
96. Gil J. M. Rego A. C. (2009) The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Brain Res. Rev. 59, 410 431.
97. Glass M., van Dellen A., Blakemore C., Hannan A. J. Faull R. L. (2004) Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 123, 207 212.
98. Goldberg A. L. (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895 899.
99. Goti D., Katzen S. M., Mez J. et al. (2004) A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J. Neurosci. 24, 10266 10279.
100. Graham R. K., Deng Y., Slow E. J. et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125, 1179 1191.
101. Gray M., Shirasaki D. I., Cepeda C. et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28, 6182 6195.
102. Green H. (1993) Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell 74, 955 956.
103. Grunewald T. Beal M. F. (1999) Bioenergetics in Huntington's disease. Ann. NY Acad. Sci. 893, 203 213.
104. Gu M., Gash M. T., Mann V. M., Javoy-Agid F., Cooper J. M. Schapira A. H. (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39, 385 389.
105. Gunawardena S., Her L. S., Brusch R. G., Laymon R. A., Niesman I. R., Gordesky-Gold B., Sintasath L., Bonini N. M. Goldstein L. S. (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40, 25 40.
106. Haacke A., Broadley S. A., Boteva R., Tzvetkov N., Hartl F. U. Breuer P. (2006) Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. Hum. Mol. Genet. 15, 555 568.
107. Hackam A. S., Singaraja R., Zhang T., Gan L. Hayden M. R. (1999) In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. Hum. Mol. Genet. 8, 25 33.
108. Hackam A. S., Yassa A. S., Singaraja R. et al. (2000) Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain. J. Biol. Chem. 275, 41299 41308.
109. Hay D. G., Sathasivam K., Tobaben S. et al. (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 13, 1389 1405.
110. Helmlinger D., Hardy S., Sasorith S. et al. (2004) Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum. Mol. Genet. 13, 1257 1265.
111. Helmlinger D., Hardy S., Abou-Sleymane G. et al. (2006) Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol. 4, 432 445.
112. Heng M. Y., Tallaksen-Greene S. J., Detloff P. J. Albin R. L. (2007) Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease. J. Neurosci. 27, 8989 8998.
113. Heng M. Y., Detloff P. J. Albin R. L. (2008) Rodent genetic models of Huntington disease. Neurobiol. Dis. 32, 1 9.
114. Hickey M. A., Kosmalska A., Enayati J., Cohen R., Zeitlin S., Levine M. S. Chesselet M. F. (2008) Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 157, 280 295.
115. Hirakawa T., Rokutan K., Nikawa T. Kishi K. (1996) Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology 111, 345 357. (Pubitemid 26256722)
116. Hockly E., Cordery P. M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C. M., Hannan A. J. Bates G. P. (2002) Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 51, 235 242.
117. Hockly E., Richon V. M., Woodman B. et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 2041 2046.
118. Hockly E., Tse J., Barker A. L. et al. (2006) Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiol. Dis. 21, 228 236.
119. Hodgson J. G., Agopyan N., Gutekunst C. A. et al. (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23, 181 192.
120. Hoffner G., Island M. L. Djian P. (2005) Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J. Neurochem. 95, 125 136.
121. Hollenbach B., Scherzinger E., Schweiger K., Lurz R., Lehrach H. Wanker E. E. (1999) Aggregation of truncated GST-HD exon 1 fusion proteins containing normal range and expanded glutamine repeats. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 991 994.
122. Holmberg M., Duyckaerts C., Durr A. et al. (1998) Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum. Mol. Genet. 7, 913 918.
123. Huen N. Y. Chan H. Y. (2005) Dynamic regulation of molecular chaperone gene expression in polyglutamine disease. Biochem. Biophys. Res. Commun. 334, 1074 1084.
124. Hughes R. E. Olson J. M. (2001) Therapeutic opportunities in polyglutamine disease. Nat. Med. 7, 419 423.
125. Humbert S., Bryson E. A., Cordelieres F. P., Connors N. C., Datta S. R., Finkbeiner S., Greenberg M. E. Saudou F. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2, 831 837.
126. Huntington Study Group (2001) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57, 397 404.
127. Huynh D. P., Del Bigio M. R., Ho D. H. Pulst S. M. (1999) Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. Ann. Neurol. 45, 232 241.
128. Huynh D. P., Figueroa K., Hoang N. Pulst S. M. (2000) Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat. Genet. 26, 44 50.
129. Huynh D. P., Yang H. T., Vakharia H., Nguyen D. Pulst S. M. (2003) Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Hum. Mol. Genet. 12, 1485 1496.
130. Igarashi S., Koide R., Shimohata T. et al. (1998) Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat. Genet. 18, 111 117.
131. Ikeda H., Yamaguchi M., Sugai S., Aze Y., Narumiya S. Kakizuka A. (1996) Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat. Genet. 13, 196 202. (Pubitemid 26000440)
132. Imbriano C., Bolognese F., Gurtner A., Piaggio G. Mantovani R. (2001) HSP-CBF is an NF-Y-dependent coactivator of the heat shock promoters CCAAT boxes. J. Biol. Chem. 276, 26332 26339.
133. Ishihara K., Yamagishi N., Saito Y., Adachi H., Kobayashi Y., Sobue G., Ohtsuka K. Hatayama T. (2003) Hsp105alpha suppresses the aggregation of truncated androgen receptor with expanded CAG repeats and cell toxicity. J. Biol. Chem. 278, 25143 25150.
134. Ishikawa K., Fujigasaki H., Saegusa H. et al. (1999) Abundant expression and cytoplasmic aggregations of [alpha]1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6. Hum. Mol. Genet. 8, 1185 1193.
135. Jana N. R., Tanaka M., Wang G. Nukina N. (2000) Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet. 9, 2009 2018.
136. Jana N. R., Zemskov E. A., Wang G. Nukina N. (2001) Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10, 1049 1059.
137. Jana N. R., Dikshit P., Goswami A., Kotliarova S., Murata S., Tanaka K. Nukina N. (2005) Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem. 280, 11635 11640.
138. Jen J. C., Yue Q., Karrim J., Nelson S. F. Baloh R. W. (1998) Spinocerebellar ataxia type 6 with positional vertigo and acetazolamide responsive episodic ataxia. J. Neurol. Neurosurg. Psychiatry 65, 565 568.
139. Jiang J., Ballinger C. A., Wu Y., Dai Q., Cyr D. M., Hohfeld J. Patterson C. (2001) CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J. Biol. Chem. 276, 42938 42944.
140. Jorgensen N. D., Andresen J. M., Lagalwar S. et al. (2009) Phosphorylation of ATXN1 at Ser776 in the cerebellum. J. Neurochem. 110, 675 686.
141. Kahlem P., Terre C., Green H. Djian P. (1996) Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc. Natl Acad. Sci. USA 93, 14580 14585.
142. Kahlem P., Green H. Djian P. (1998) Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol. Cell 1, 595 601.
143. Kariya S., Hirano M., Nagai Y., Furiya Y., Fujikake N., Toda T. Ueno S. (2005) Humanin attenuates apoptosis induced by DRPLA proteins with expanded polyglutamine stretches. J. Mol. Neurosci. 25, 165 169.
144. Karpuj M. V., Garren H., Slunt H., Price D. L., Gusella J., Becher M. W. Steinman L. (1999) Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl Acad. Sci. USA 96, 7388 7393.
145. Karpuj M. V., Becher M. W., Springer J. E., Chabas D., Youssef S., Pedotti R., Mitchell D. Steinman L. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8, 143 149.
146. Katsuno M., Adachi H., Kume A. et al. (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35, 843 854.
147. Katsuno M., Adachi H., Doyu M., Minamiyama M., Sang C., Kobayashi Y., Inukai A. Sobue G. (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat. Med. 9, 768 773.
148. Katsuno M., Sang C., Adachi H., Minamiyama M., Waza M., Tanaka F., Doyu M. Sobue G. (2005) Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc. Natl Acad. Sci. USA 102, 16801 16806.
149. Kaytor M. D., Duvick L. A., Skinner P. J., Koob M. D., Ranum L. P. Orr H. T. (1999) Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7. Hum. Mol. Genet. 8, 1657 1664.
150. Kazemi-Esfarjani P. Benzer S. (2000) Genetic suppression of polyglutamine toxicity in Drosophila. Science 287, 1837 1840.
151. Kegel K. B., Sapp E., Yoder J. et al. (2005) Huntingtin associates with acidic phospholipids at the plasma membrane. J. Biol. Chem. 280, 36464 36473.
152. Khan L. A., Bauer P. O., Miyazaki H., Lindenberg K. S., Landwehrmeyer B. G. Nukina N. (2006) Expanded polyglutamines impair synaptic transmission and ubiquitin-proteasome system in Caenorhabditis elegans. J. Neurochem. 98, 576 587.
153. Klement I. A., Skinner P. J., Kaytor M. D., Yi H., Hersch S. M., Clark H. B., Zoghbi H. Y. Orr H. T. (1998) Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95, 41 53.
154. Kobayashi Y., Kume A., Li M., Doyu M., Hata M., Ohtsuka K. Sobue G. (2000) Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem. 275, 8772 8778.
155. Kotliarova S., Jana N. R., Sakamoto N. et al. (2005) Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates. J. Neurochem. 93, 641 653.
156. Koyano S., Uchihara T., Fujigasaki H., Nakamura A., Yagishita S. Iwabuchi K. (1999) Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: triple-labeling immunofluorescent study. Neurosci. Lett. 273, 117 120.
157. Koyano S., Iwabuchi K., Yagishita S., Kuroiwa Y. Uchihara T. (2002) Paradoxical absence of nuclear inclusion in cerebellar Purkinje cells of hereditary ataxias linked to CAG expansion. J. Neurol. Neurosurg. Psychiatry 73, 450 452.
158. Kuhn A., Goldstein D. R., Hodges A. et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 16, 1845 1861.
159. Kwiatkowski T. J. Jr., Bosco D. A., Leclerc A. L. et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205 1208.
160. La Spada A. R., Wilson E. M., Lubahn D. B., Harding A. E. Fischbeck K. H. (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77 79.
161. La Spada A. R., Fu Y. H., Sopher B. L. et al. (2001) Polyglutamine- expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 31, 913 927.
162. LaFevre-Bernt M. A. Ellerby L. M. (2003) Kennedy's disease. Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 and enhances cell death. J. Biol. Chem. 278, 34918 34924.
163. Lai A. Frishman W. H. (2005) Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol. Rev. 13, 285 292.
164. Landwehrmeyer G. B., Dubois B., de Yebenes J. G. et al. (2007) Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann. Neurol. 62, 262 272.
165. Lazic S. E., Grote H. E., Blakemore C., Hannan A. J., van Dellen A., Phillips W. Barker R. A. (2006) Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur. J. Neurosci. 23, 1829 1838.
166. Lee Y., Samaco R. C., Gatchel J. R., Thaller C., Orr H. T. Zoghbi H. Y. (2008) miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat. Neurosci. 11, 1137 1139.
167. Lesort M., Lee M., Tucholski J. Johnson G. V. (2003) Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 278, 3825 3830.
168. Levine M. S., Klapstein G. J., Koppel A. et al. (2002a) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58, 515 532.
169. Li P., Nijhawan D., Budihardjo I., Srinivasula S. M., Ahmad M., Alnemri E. S. Wang X 1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479 489.
170. Li M., Nakagomi Y., Kobayashi Y. et al. (1998) Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am. J. Pathol. 153, 695 701. (Pubitemid 28419023)
171. Li H., Li S. H., Johnston H., Shelbourne P. F. Li X. J. (2000a) Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat. Genet. 25, 385 389.
172. Li S. H., Lam S., Cheng A. L. Li X. J. (2000b) Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. Hum. Mol. Genet. 9, 2859 2867.
173. Li H., Li S. H., Yu Z. X., Shelbourne P. Li X. J. (2001) Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci. 21, 8473 8481.
174. Li F., Macfarlan T., Pittman R. N. Chakravarti D. (2002a) Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J. Biol. Chem. 277, 45004 45012.
175. Li S. H., Cheng A. L., Zhou H., Lam S., Rao M., Li H. Li X. J. (2002b) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol. 22, 1277 1287.
176. Li H., Wyman T., Yu Z. X., Li S. H. Li X. J. (2003) Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum. Mol. Genet. 12, 2021 2030.
177. Li J. Y., Popovic N. Brundin P. (2005) The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2, 447 464.
178. Lin C. H., Tallaksen-Greene S., Chien W. M. et al. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 10, 137 144.
179. Lombardi M. S., Jaspers L., Spronkmans C., Gellera C., Taroni F., Maria E. D., Donato S. D. Kaemmerer W. F. (2009) A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol. 217, 312 319.
180. Lunkes A. Mandel J. L. (1998) A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum. Mol. Genet. 7, 1355 1361.
181. Lunkes A., Trottier Y., Fagart J., Schultz P., Zeder-Lutz G., Moras D. Mandel J. L. (1999) Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 1013 1019.
182. Lunkes A., Lindenberg K. S., Ben-Haiem L., Weber C., Devys D., Landwehrmeyer G. B., Mandel J. L. Trottier Y. (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell 10, 259 269.
183. Luo S., Vacher C., Davies J. E. Rubinsztein D. C. (2005) Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J. Cell Biol. 169, 647 656.
184. Luthi-Carter R., Strand A. D., Hanson S. A. et al. (2002) Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet. 11, 1927 1937.
185. Mangiarini L., Sathasivam K., Seller M. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493 506.
186. Mao R., Aylsworth A. S., Potter N. et al. (2002) Childhood-onset ataxia: testing for large CAG-repeats in SCA2 and SCA7. Am. J. Med. Genet. 110, 338 345.
187. Marsh J. L., Lukacsovich T. Thompson L. M. (2009) Animal models of polyglutamine diseases and therapeutic approaches. J. Biol. Chem. 284, 7431 7435.
188. Martindale D., Hackam A., Wieczorek A. et al. (1998) Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet. 18, 150 154.
189. Masino L., Nicastro G., Menon R. P., Dal Piaz F., Calder L. Pastore A. (2004) Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3. J. Mol. Biol. 344, 1021 1035.
190. Matilla A. Radrizzani M. (2005) The Anp32 family of proteins containing leucine-rich repeats. Cerebellum 4, 7 18.
191. Matilla A., Koshy B. T., Cummings C. J., Isobe T., Orr H. T. Zoghbi H. Y. (1997) The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 389, 974 978.
192. Matilla A., Gorbea C., Einum D. D. et al. (2001) Association of ataxin-7 with the proteasome subunit S4 of the 19S regulatory complex. Hum. Mol. Genet. 10, 2821 2831.
193. 2+ channel - loss-of-function cellular model of SCA6. Neurobiol. Dis. 17, 198 204.
194. McCampbell A., Taylor J. P., Taye A. A. et al. (2000) CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 9, 2197 2202.
195. Menalled L. B., Sison J. D., Wu Y., Olivieri M., Li X. J., Li H., Zeitlin S. Chesselet M. F. (2002) Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci. 22, 8266 8276.
196. Menalled L. B., Sison J. D., Dragatsis I., Zeitlin S. Chesselet M. F. (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 465, 11 26.
197. Merienne K., Helmlinger D., Perkin G. R., Devys D. Trottier Y. (2003) Polyglutamine expansion induces a protein-damaging stress connecting heat shock protein 70 to the JNK pathway. J. Biol. Chem. 278, 16957 16967.
198. Merry D. E., Kobayashi Y., Bailey C. K., Taye A. A. Fischbeck K. H. (1998) Cleavage, aggregation and toxicity of the expanded androgen receptor in spinal and bulbar muscular atrophy. Hum. Mol. Genet. 7, 693 701. (Pubitemid 28152269)
199. Milakovic T. Johnson G. V. (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J. Biol. Chem. 280, 30773 30782.
200. Miller V. M., Nelson R. F., Gouvion C. M., Williams A., Rodriguez-Lebron E., Harper S. Q., Davidson B. L., Rebagliati M. R. Paulson H. L. (2005) CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J. Neurosci. 25, 9152 9161.
201. Minamiyama M., Katsuno M., Adachi H. et al. (2004) Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 13, 1183 1192.
202. Mitsui K., Nakayama H., Akagi T., Nekooki M., Ohtawa K., Takio K., Hashikawa T. Nukina N. (2002) Purification of polyglutamine aggregates and identification of elongation factor-1alpha and heat shock protein 84 as aggregate-interacting proteins. J. Neurosci. 22, 9267 9277.
203. Miyazaki H., Oyama F., Wong H. K., Kaneko K., Sakurai T., Tamaoka A. Nukina N. (2007) BACE1 modulates filopodia-like protrusions induced by sodium channel beta4 subunit. Biochem. Biophys. Res. Commun. 361, 43 48.
204. Mizutani A., Wang L., Rajan H., Vig P. J., Alaynick W. A., Thaler J. P. Tsai C. C. (2005) Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1. EMBO J. 24, 3339 3351.
205. Moseley M. L., Zu T., Ikeda Y. et al. (2006) Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet. 38, 758 769.
206. Muchowski P. J. (2002) Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 35, 9 12.
207. Muchowski P. J., Schaffar G., Sittler A., Wanker E. E., Hayer-Hartl M. K. Hartl F. U. (2000) Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl Acad. Sci. USA 97, 7841 7846.
208. Mueller T., Breuer P., Schmitt I., Evert B. O. Wullner U. (2009) CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Hum. Mol. Genet. Epub ahead of print, doi:.
209. Mukherjee S., Thomas M., Dadgar N., Lieberman A. P. Iniguez-Lluhl J. A. (2009) SUMO modification of the androgen receptor attenuates polyglutamine-mediated aggregation. J. Biol. Chem. 284, 21296 21306.
210. Muller S., Hoege C., Pyrowolakis G. Jentsch S. (2001) SUMO, ubiquitin's mysterious cousin. Nat. Rev. Mol. Cell Biol. 2, 202 210.
211. Nagai Y., Fujikake N., Ohno K. et al. (2003) Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum. Mol. Genet. 12, 1253 1259.
212. Nagai Y., Inui T., Popiel H. A., Fujikake N., Hasegawa K., Urade Y., Goto Y., Naiki H. Toda T. (2007) A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 14, 332 340.
213. Nakamura K., Jeong S. Y., Uchihara T., Anno M., Nagashima K., Nagashima T., Ikeda S., Tsuji S. Kanazawa I. (2001) SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet. 10, 1441 1448.
214. Naver B., Stub C., Moller M., Fenger K., Hansen A. K., Hasholt L. Sorensen S. A. (2003) Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 122, 1049 1057.
215. Nguyen T., Hamby A. Massa S. M. (2005) Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc. Natl Acad. Sci. USA 102, 11840 11845.
216. Nishitoh H., Matsuzawa A., Tobiume K., Saegusa K., Takeda K., Inoue K., Hori S., Kakizuka A. Ichijo H. (2002) ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 16, 1345 1355.
217. Nucifora F. C. Jr., Sasaki M., Peters M. F. et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423 2428.
218. Nucifora F. C. Jr., Ellerby L. M., Wellington C. L. et al. (2003) Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. J. Biol. Chem. 278, 13047 13055.
219. Obrietan K. Hoyt K. R. (2004) CRE-mediated transcription is increased in Huntington's disease transgenic mice. J. Neurosci. 24, 791 796.
220. Okamura-Oho Y., Miyashita T., Nagao K., Shima S., Ogata Y., Katada T., Nishina H. Yamada M. (2003) Dentatorubral-pallidoluysian atrophy protein is phosphorylated by c-Jun NH2-terminal kinase. Hum. Mol. Genet. 12, 1535 1542.
221. Okazawa H. (2003) Polyglutamine diseases: a transcription disorder? Cell. Mol. Life Sci. 60, 1427 1439.
222. Okazawa H., Rich T., Chang A. et al. (2002) Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron 34, 701 713.
223. Oliveira J. M., Jekabsons M. B., Chen S., Lin A., Rego A. C., Goncalves J., Ellerby L. M. Nicholls D. G. (2007) Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J. Neurochem. 101, 241 249.
224. Ona V. O., Li M., Vonsattel J. P. et al. (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399, 263 267.
225. Orr H. T. (2001) Qs in the nucleus. Neuron 31, 875 876.
226. Orr A. L., Li S., Wang C. E. et al. (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 28, 2783 2792.
227. Oyama F., Miyazaki H., Sakamoto N. et al. (2006) Sodium channel beta4 subunit: down-regulation and possible involvement in neuritic degeneration in Huntington's disease transgenic mice. J. Neurochem. 98, 518 529.
228. Palhan V. B., Chen S., Peng G. H., Tjernberg A., Gamper A. M., Fan Y., Chait B. T., La Spada A. R. Roeder R. G. (2005) Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc. Natl Acad. Sci. USA 102, 8472 8477.
229. Panov A. V., Gutekunst C. A., Leavitt B. R., Hayden M. R., Burke J. R., Strittmatter W. J. Greenamyre J. T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5, 731 736.
230. Pardo R., Colin E., Regulier E., Aebischer P., Deglon N., Humbert S. Saudou F. (2006) Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J. Neurosci. 26, 1635 1645.
231. Parker J. A., Holbert S., Lambert E., Abderrahmane S. Neri C. (2004) Genetic and pharmacological suppression of polyglutamine-dependent neuronal dysfunction in Caenorhabditis elegans. J. Mol. Neurosci. 23, 61 68.
232. Parker J. A., Arango M., Abderrahmane S., Lambert E., Tourette C., Catoire H. Neri C. (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 37, 349 350.
233. Paulson H. L. (1999) Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold. Am. J. Hum. Genet. 64, 339 345.
234. Paulson H. L. (2000) Toward an understanding of polyglutamine neurodegeneration. Brain Pathol. 10, 293 299.
235. Paulson H. L., Perez M. K., Trottier Y. et al. (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19, 333 344.
236. Peng Q., Masuda N., Jiang M., Li Q., Zhao M., Ross C. A. Duan W. (2008) The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp. Neurol. 210, 154 163.
237. Perez M. K., Paulson H. L., Pendse S. J., Saionz S. J., Bonini N. M. Pittman R. N. (1998) Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J. Cell Biol. 143, 1457 1470.
238. Perutz M. F., Johnson T., Suzuki M. Finch J. T. (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl Acad. Sci. USA 91, 5355 5358.
239. Perutz M. F., Pope B. J., Owen D., Wanker E. E. Scherzinger E. (2002) Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid beta-peptide of amyloid plaques. Proc. Natl Acad. Sci. USA 99, 5596 5600.
240. Peters M. F., Nucifora F. C. Jr., Kushi J., Seaman H. C., Cooper J. K., Herring W. J., Dawson V. L., Dawson T. M. Ross C. A. (1999) Nuclear targeting of mutant Huntingtin increases toxicity. Mol. Cell. Neurosci. 14, 121 128.
241. Pfister E. L., Kennington L., Straubhaar J. et al. (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol. 19, 774 778.
242. Poirier M. A., Jiang H. Ross C. A. (2005) A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. Hum. Mol. Genet. 14, 765 774.
243. Pollitt S. K., Pallos J., Shao J., Desai U. A., Ma A. A., Thompson L. M., Marsh J. L. Diamond M. I. (2003) A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron 40, 685 694.
244. Pozzi C., Valtorta M., Tedeschi G., Galbusera E., Pastori V., Bigi A., Nonnis S., Grassi E. Fusi P. (2008) Study of subcellular localization and proteolysis of ataxin-3. Neurobiol. Dis. 30, 190 200.
245. Puranam K. L., Wu G., Strittmatter W. J. Burke J. R. (2006) Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria. Biochem. Biophys. Res. Commun. 341, 607 613.
246. Qiu Z., Norflus F., Singh B. et al. (2006) Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J. Biol. Chem. 281, 16672 16680.
247. Ranganathan S., Harmison G. G., Meyertholen K., Pennuto M., Burnett B. G. Fischbeck K. H. (2009) Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum. Mol. Genet. 18, 27 42.
248. Rangone H., Poizat G., Troncoso J., Ross C. A., MacDonald M. E., Saudou F. Humbert S. (2004) The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur. J. Neurosci. 19, 273 279.
249. Reddy P. H., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell W. O. Jr., Miller G. Tagle D. A. (1998) Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet. 20, 198 202.
250. Riley B. E., Zoghbi H. Y. Orr H. T. (2005) SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on functional nuclear localization signal. J. Biol. Chem. 280, 21942 21948.
251. Rockabrand E., Slepko N., Pantalone A. et al. (2007) The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum. Mol. Genet. 16, 61 77.
252. van Roon-Mom W. M., Reid S. J., Jones A. L., MacDonald M. E., Faull R. L. Snell R. G. (2002) Insoluble TATA-binding protein accumulation in Huntington's disease cortex. Brain Res. Mol. Brain Res. 109, 1 10.
253. Ross C. A. Poirier M. A. (2004) Protein aggregation and neurodegenerative disease. Nat. Med. 10 (Suppl. S10 S17.
254. Ross C. A., Wood J. D., Schilling G., Peters M. F., Nucifora F. C. Jr., Cooper J. K., Sharp A. H., Margolis R. L. Borchelt D. R. (1999) Polyglutamine pathogenesis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 1005 1011.
255. Rubinsztein D. C., Wyttenbach A. Rankin J. (1999) Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts? J. Med. Genet. 36, 265 270.
256. Ryu H., Lee J., Hagerty S. W., Soh B. Y., McAlpin S. E., Cormier K. A., Smith K. M. Ferrante R. J. (2006) ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl Acad. Sci. USA 103, 19176 19181.
257. Sanchez I., Xu C. J., Juo P., Kakizaka A., Blenis J. Yuan J. (1999) Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22, 623 633.
258. Sanchez I., Mahlke C. Yuan J. (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421, 373 379.
259. Sanchez-Pernaute R., Garcia-Segura J. M., del Barrio Alba A., Viano J. de Yebenes J. G. (1999) Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology 53, 806 812.
260. Sarge K. D. Park-Sarge O. K. (2009) Sumoylation and human disease pathogenesis. Trends Biochem. Sci. 34, 200 205.
261. Sarkar S., Davies J. E., Huang Z., Tunnacliffe A. Rubinsztein D. C. (2007a) Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 282, 5641 5652.
262. Sarkar S., Perlstein E. O., Imarisio S. et al. (2007b) Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 3, 331 338.
263. Sarkar S., Krishna G., Imarisio S., Saiki S., O'Kane C. J. Rubinsztein D. C. (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum. Mol. Genet. 17, 170 178.
264. Sato T., Oyake M., Nakamura K. et al. (1999) Transgenic mice harboring a full-length human mutant DRPLA gene exhibit age-dependent intergenerational and somatic instabilities of CAG repeats comparable with those in DRPLA patients. Hum. Mol. Genet. 8, 99 106.
265. Saudou F., Finkbeiner S., Devys D. Greenberg M. E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55 66.
266. Saydoff J. A., Garcia R. A., Browne S. E. et al. (2006) Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiol. Dis. 24, 455 465.
267. Schiefer J., Landwehrmeyer G. B., Luesse H. G., Sprunken A., Puls C., Milkereit A., Milkereit E. Kosinski C. M. (2002) Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord. 17, 748 757.
268. Schiefer J., Sprunken A., Puls C., Luesse H. G., Milkereit A., Milkereit E., Johann V. Kosinski C. M. (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res. 1019, 246 254.
269. Schilling G., Becher M. W., Sharp A. H. et al. (1999a) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397 407.
270. Schilling G., Wood J. D., Duan K. et al. (1999b) Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. Neuron 24, 275 286.
271. Schilling G., Coonfield M. L., Ross C. A. Borchelt D. R. (2001) Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 315, 149 153.
272. Schilling B., Gafni J., Torcassi C. et al. (2006) Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. J. Biol. Chem. 281, 23686 23697.
273. Schmidt T., Landwehrmeyer G. B., Schmitt I. et al. (1998) An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol. 8, 669 679.
274. Schmidt T., Lindenberg K. S., Krebs A., Schols L., Laccone F., Herms J., Rechsteiner M., Riess O. Landwehrmeyer G. B. (2002) Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann. Neurol. 51, 302 310.
275. Schols L., Bauer P., Schmidt T., Schulte T. Riess O. (2004) Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 3, 291 304.
276. Shao J. Diamond M. I. (2007) Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 16 (Spec No. 2) R115 R123.
277. Shelbourne P. F., Killeen N., Hevner R. F. et al. (1999) A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum. Mol. Genet. 8, 763 774.
278. Shibata H., Huynh D. P. Pulst S. M. (2000) A novel protein with RNA-binding motifs interacts with ataxin-2. Hum. Mol. Genet. 9, 1303 1313.
279. Shimohata T., Nakajima T., Yamada M. et al. (2000) Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet. 26, 29 36.
280. Sieradzan K. A., Mechan A. O., Jones L., Wanker E. E., Nukina N. Mann D. M. (1999) Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp. Neurol. 156, 92 99.
281. Skinner P. J., Koshy B. T., Cummings C. J., Klement I. A., Helin K., Servadio A., Zoghbi H. Y. Orr H. T. (1997) Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 389, 971 974.
282. Slow E. J., van Raamsdonk J., Rogers D. et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12, 1555 1567.
283. Smith D. L., Woodman B., Mahal A., Sathasivam K., Ghazi-Noori S., Lowden P. A., Bates G. P. Hockly E. (2003) Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann. Neurol. 54, 186 196. (Pubitemid 36909617)
284. Smith K. M., Matson S., Matson W. R., Cormier K., Del Signore S. J., Hagerty S. W., Stack E. C., Ryu H. Ferrante R. J. (2006) Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762, 616 626.
285. Spampanato J., Gu X., Yang X. W. Mody I. (2008) Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease. Neuroscience 157, 606 620.
286. Stack E. C., Kubilus J. K., Smith K., Cormier K., Del Signore S. J., Guelin E., Ryu H., Hersch S. M. Ferrante R. J. (2005) Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol. 490, 354 370.
287. Stack E. C., Smith K. M., Ryu H. et al. (2006) Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim. Biophys. Acta 1762, 373 380.
288. Stack E. C., Del Signore S. J., Luthi-Carter R. et al. (2007) Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet. 16, 1164 1175.
289. Steffan J. S., Kazantsev A., Spasic-Boskovic O. et al. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA 97, 6763 6768.
290. Steffan J. S., Agrawal N., Pallos J. et al. (2004) SUMO modification of Huntingtin and Huntington's disease pathology. Science 304, 100 104.
291. Stenoien D. L., Cummings C. J., Adams H. P., Mancini M. G., Patel K., DeMartino G. N., Marcelli M., Weigel N. L. Mancini M. A. (1999) Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol. Genet. 8, 731 741.
292. Stenoien D. L., Mielke M. Mancini M. A. (2002) Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components. Nat. Cell Biol. 4, 806 810.
293. St-Pierre J., Drori S., Uldry M. et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127, 397 408.
294. Strom A. L., Forsgren L. Holmberg M. (2005) A role for both wild-type and expanded ataxin-7 in transcriptional regulation. Neurobiol. Dis. 20, 646 655.
295. Sun X. M., Butterworth M., MacFarlane M., Dubiel W., Ciechanover A. Cohen G. M. (2004) Caspase activation inhibits proteasome function during apoptosis. Mol. Cell 14, 81 93.
296. Sun J., Xu H., Negi S., Subramony S. H. Hebert M. D. (2007) Differential effects of polyglutamine proteins on nuclear organization and artificial reporter splicing. J. Neurosci. Res. 85, 2306 2317.
297. Szebenyi G., Morfini G. A., Babcock A. et al. (2003) Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40, 41 52.
298. Tait D., Riccio M., Sittler A., Scherzinger E., Santi S., Ognibene A., Maraldi N. M., Lehrach H. Wanker E. E. (1998) Ataxin-3 is transported into the nucleus and associates with the nuclear matrix. Hum. Mol. Genet. 7, 991 997.
299. Tallaksen-Greene S. J., Crouse A. B., Hunter J. M., Detloff P. J. Albin R. L. (2005) Neuronal intranuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice. Neuroscience 131, 843 852.
300. Tanaka M., Morishima I., Akagi T., Hashikawa T. Nukina N. (2001) Intra- and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases. J. Biol. Chem. 276, 45470 45475.
301. Tanaka M., Machida Y., Nishikawa Y., Akagi T., Hashikawa T., Fujisawa T. Nukina N. (2003) Expansion of polyglutamine induces the formation of quasi-aggregate in the early stage of protein fibrillization. J. Biol. Chem. 278, 34717 34724.
302. Tanaka M., Machida Y., Niu S., Ikeda T., Jana N. R., Doi H., Kurosawa M., Nekooki M. Nukina N. (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10, 148 154.
303. Tanese N. Tjian R. (1993) Coactivators and TAFs: a new class of eukaryotic transcription factors that connect activators to the basal machinery. Cold Spring Harb. Symp. Quant. Biol. 58, 179 185.
304. Tang T. S., Tu H., Chan E. Y., Maximov A., Wang Z., Wellington C. L., Hayden M. R. Bezprozvanny I. (2003) Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39, 227 239.
305. Tang T. S., Guo C., Wang H., Chen X. Bezprozvanny I. (2009) Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. J. Neurosci. 29, 1257 1266.
306. Taylor J., Grote S. K., Xia J., Vandelft M., Graczyk J., Ellerby L. M., La Spada A. R. Truant R. (2006) Ataxin-7 can export from the nucleus via a conserved exportin-dependent signal. J. Biol. Chem. 281, 2730 2739.
307. Terashima T., Kawai H., Fujitani M., Maeda K. Yasuda H. (2002) SUMO-1 co-localized with mutant atrophin-1 with expanded polyglutamines accelerates intranuclear aggregation and cell death. Neuroreport 13, 2359 2364.
308. Thakur A. K., Jayaraman M., Mishra R. et al. (2009) Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat. Struct. Mol. Biol. 16, 380 389.
309. Tokui K., Adachi H., Waza M. et al. (2009) 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum. Mol. Genet. 18, 898 910.
310. Trottier Y., Cancel G., An-Gourfinkel I., Lutz Y., Weber C., Brice A., Hirsch E. Mandel J. L. (1998) Heterogeneous intracellular localization and expression of ataxin-3. Neurobiol. Dis. 5, 335 347.
311. Tsai H. F., Tsai H. J. Hsieh M. (2004) Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells. Biochem. Biophys. Res. Commun. 324, 1274 1282.
312. Tsuda H., Jafar-Nejad H., Patel A. J. et al. (2005) The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. Cell 122, 633 644.
313. Uchihara T., Fujigasaki H., Koyano S., Nakamura A., Yagishita S. Iwabuchi K. (2001) Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias - triple-labeling immunofluorescence study. Acta Neuropathol. 102, 149 152.
314. Ueda H., Goto J., Hashida H., Lin X., Oyanagi K., Kawano H., Zoghbi H. Y., Kanazawa I. Okazawa H. (2002) Enhanced SUMOylation in polyglutamine diseases. Biochem. Biophys. Res. Commun. 293, 307 313.
315. Verma R., Oania R., Graumann J. Deshaies R. J. (2004) Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system. Cell 118, 99 110.
316. Vierra-Green C. A., Orr H. T., Zoghbi H. Y. Ferrington D. A. (2005) Identification of a novel phosphorylation site in ataxin-1. Biochim. Biophys. Acta 1744, 11 18.
317. Wang G., Ide K., Nukina N., Goto J., Ichikawa Y., Uchida K., Sakamoto T. Kanazawa I. (1997) Machado-Joseph disease gene product identified in lymphocytes and brain. Biochem. Biophys. Res. Commun. 233, 476 479.
318. Wang G. H., Mitsui K., Kotliarova S., Yamashita A., Nagao Y., Tokuhiro S., Iwatsubo T., Kanazawa I. Nukina N. (1999) Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. Neuroreport 10, 2435 2438.
319. Wang G., Sawai N., Kotliarova S., Kanazawa I. Nukina N. (2000) Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Hum. Mol. Genet. 9, 1795 1803.
320. Wang X., Zhu S., Drozda M., Zhang W., Stavrovskaya I. G., Cattaneo E., Ferrante R. J., Kristal B. S. Friedlander R. M. (2003) Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 10483 10487.
321. Wang H. L., Yeh T. H., Chou A. H., Kuo Y. L., Luo L. J., He C. Y., Huang P. C. Li A. H. (2006) Polyglutamine-expanded ataxin-7 activates mitochondrial apoptotic pathway of cerebellar neurons by upregulating Bax and downregulating Bcl-x(L). Cell. Signal. 18, 541 552.
322. Wang H., Lim P. J., Karbowski M. Monteiro M. J. (2009) Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum. Mol. Genet. 18, 737 752.
323. Wanker E. E. (2000) Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations. J. Biol. Chem. 381, 937 942.
324. Warby S. C., Doty C. N., Graham R. K., Shively J., Singaraja R. R. Hayden M. R. (2009) Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol. Cell. Neurosci. 40, 121 127.
325. Warrick J. M., Chan H. Y., Gray-Board G. L., Chai Y., Paulson H. L. Bonini N. M. (1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 23, 425 428.
326. Watase K., Gatchel J. R., Sun Y. et al. (2007) Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 4, 836 846.
327. Waza M., Adachi H., Katsuno M., Minamiyama M., Sang C., Tanaka F., Inukai A., Doyu M. Sobue G. (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11, 1088 1095.
328. Wellington C. L. Hayden M. R. (2000) Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clin. Genet. 57, 1 10.
329. Wellington C. L., Ellerby L. M., Hackam A. S. et al. (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273, 9158 9167.
330. Wellington C. L., Singaraja R., Ellerby L. et al. (2000) Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem. 275, 19831 19838.
331. Wellington C. L., Ellerby L. M., Gutekunst C. A. et al. (2002) Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22, 7862 7872.
332. Weydt P., Pineda V. V., Torrence A. E. et al. (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 4, 349 362.
333. Wheeler V. C., White J. K., Gutekunst C. A. et al. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet. 9, 503 513.
334. Wheeler V. C., Gutekunst C. A., Vrbanac V. et al. (2002) Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum. Mol. Genet. 11, 633 640.
335. Williams A., Sarkar S., Cuddon P. et al. (2008) Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol. 4, 295 305.
336. Williams A. J., Knutson T. M., Colomer Gould V. F. Paulson H. L. (2009) In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol. Dis. 33, 342 353.
337. Wong H. K., Bauer P. O., Kurosawa M. et al. (2008) Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism. Hum. Mol. Genet. 17, 3223 3235.
338. Wood N. I., Pallier P. N., Wanderer J. Morton A. J. (2007) Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice. Neurobiol. Dis. 25, 342 353.
339. Woodman B., Butler R., Landles C., Lupton M. K., Tse J., Hockly E., Moffitt H., Sathasivam K. Bates G. P. (2007) The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 72, 83 97.
340. Wyttenbach A., Sauvageot O., Carmichael J., Diaz-Latoud C., Arrigo A. P. Rubinsztein D. C. (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 11, 1137 1151.
341. Xia J., Lee D. H., Taylor J., Vandelft M. Truant R. (2003) Huntingtin contains a highly conserved nuclear export signal. Hum. Mol. Genet. 12, 1393 1403.
342. Yamada M., Sato T., Tsuji S. Takahashi H. (2008) CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol. 115, 71 86.
343. Yamamoto A., Lucas J. J. Hen R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57 66.
344. Yamanaka T., Miyazaki H., Oyama F., Kurosawa M., Washizu C., Doi H. Nukina N. (2008) Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. EMBO J. 27, 827 839.
345. Yang W., Dunlap J. R., Andrews R. B. Wetzel R. (2002) Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11, 2905 2917.
346. Yang Z., Chang Y. J., Yu I. C. et al. (2007) ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat. Med. 13, 348 353.
347. Ying M., Xu R., Wu X., Zhu H., Zhuang Y., Han M. Xu T. (2006) Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA. J. Biol. Chem. 281, 12580 12586.
348. Young J. E., Garden G. A., Martinez R. A. et al. (2009) Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. J. Neurosci. 29, 1987 1997.
349. Yu Z. X., Li S. H., Nguyen H. P. Li X. J. (2002) Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum. Mol. Genet. 11, 905 914.
350. Yu Y. C., Kuo C. L., Cheng W. L., Liu C. S. Hsieh M. (2009) Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease. J. Neurosci. Res. 87, 1884 1891.
351. Yvert G., Lindenberg K. S., Picaud S., Landwehrmeyer G. B., Sahel J. A. Mandel J. L. (2000) Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum. Mol. Genet. 9, 2491 2506.
352. Yvert G., Lindenberg K. S., Devys D., Helmlinger D., Landwehrmeyer G. B. Mandel J. L. (2001) SCA7 mouse models show selective stabilization of mutant ataxin-7 and similar cellular responses in different neuronal cell types. Hum. Mol. Genet. 10, 1679 1692.
353. Zander C., Takahashi J., El Hachimi K. H., Fujigasaki H., Albanese V., Lebre A. S., Stevanin G., Duyckaerts C. Brice A. (2001) Similarities between spinocerebellar ataxia type 7 (SCA7) cell models and human brain: proteins recruited in inclusions and activation of caspase-3. Hum. Mol. Genet. 10, 2569 2579.
354. Zemskov E. A. Nukina N. (2003) Impaired degradation of PKCalpha by proteasome in a cellular model of Huntington's disease. Neuroreport 14, 1435 1438.
355. Zemskov E. A., Jana N. R., Kurosawa M., Miyazaki H., Sakamoto N., Nekooki M. Nukina N. (2003) Pro-apoptotic protein kinase C delta is associated with intranuclear inclusions in a transgenic model of Huntington's disease. J. Neurochem. 87, 395 406.
356. Zhou H., Li S. H. Li X. J. (2001) Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation. J. Biol. Chem. 276, 48417 48424.
357. Zoghbi H. Y. Orr H. T. (2000) Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217 247.
358. Zu T., Duvick L. A., Kaytor M. D., Berlinger M. S., Zoghbi H. Y., Clark H. B. Orr H. T. (2004) Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24, 8853 8861.
359. Zuccato C., Tartari M., Crotti A. et al. (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35, 76 83.